Bioengineering of Virus-like Particles for the Prevention or Treatment of Allergic Diseases
Copyright © 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology · The Korean Academy of Pediatric Allergy and Respiratory Disease..
Recent findings on the mechanism of allergen-specific immunotherapy (AIT) have revisited the role of immunoglobulin G (IgG) as the development of specific blocking IgG antibodies appeared critical for the successful suppression of T-helper 2 (Th2)-biased allergic responses. Consequently, any form of molecular AIT-promoting potent allergen-specific neutralizing antibodies would be preferred to conventional administration of allergen extracts. The potent immunogenicity of virus-like particles (VLPs) could be harnessed for that purpose. The particle size (20-200 nm) optimizes uptake by antigen-presenting cells as well as lymphatic trafficking. Moreover, the display of antigens in repetitive arrays promotes potent B cell activation for the development of sustained antibody responses. The presentation of self-antigens on the particle surface was even capable to break B cell tolerance. In this review, we describe the immunomodulatory properties of the 3 VLP-based strategies designed so far for the treatment of allergic disease: VLP packaged with CpG motifs as well as chimeric particles displaying pro-Th2/Th2 cytokines or allergens (full-length or B cell epitopes).
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
---|---|
Enthalten in: |
Allergy, asthma & immunology research - 13(2021), 1 vom: 03. Jan., Seite 23-41 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Pechsrichuang, Phornsiri [VerfasserIn] |
---|
Links: |
---|
Themen: |
Allergen |
---|
Anmerkungen: |
Date Revised 01.01.2021 published: Print Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.4168/aair.2021.13.1.23 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM317590731 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM317590731 | ||
003 | DE-627 | ||
005 | 20231225163604.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.4168/aair.2021.13.1.23 |2 doi | |
028 | 5 | 2 | |a pubmed24n1058.xml |
035 | |a (DE-627)NLM317590731 | ||
035 | |a (NLM)33191675 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Pechsrichuang, Phornsiri |e verfasserin |4 aut | |
245 | 1 | 0 | |a Bioengineering of Virus-like Particles for the Prevention or Treatment of Allergic Diseases |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 01.01.2021 | ||
500 | |a published: Print | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Copyright © 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology · The Korean Academy of Pediatric Allergy and Respiratory Disease. | ||
520 | |a Recent findings on the mechanism of allergen-specific immunotherapy (AIT) have revisited the role of immunoglobulin G (IgG) as the development of specific blocking IgG antibodies appeared critical for the successful suppression of T-helper 2 (Th2)-biased allergic responses. Consequently, any form of molecular AIT-promoting potent allergen-specific neutralizing antibodies would be preferred to conventional administration of allergen extracts. The potent immunogenicity of virus-like particles (VLPs) could be harnessed for that purpose. The particle size (20-200 nm) optimizes uptake by antigen-presenting cells as well as lymphatic trafficking. Moreover, the display of antigens in repetitive arrays promotes potent B cell activation for the development of sustained antibody responses. The presentation of self-antigens on the particle surface was even capable to break B cell tolerance. In this review, we describe the immunomodulatory properties of the 3 VLP-based strategies designed so far for the treatment of allergic disease: VLP packaged with CpG motifs as well as chimeric particles displaying pro-Th2/Th2 cytokines or allergens (full-length or B cell epitopes) | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a CpG motif | |
650 | 4 | |a Nanoparticles | |
650 | 4 | |a allergen | |
650 | 4 | |a autoantibodies | |
650 | 4 | |a blocking antibodies | |
700 | 1 | |a Namwongnao, Supannika |e verfasserin |4 aut | |
700 | 1 | |a Jacquet, Alain |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Allergy, asthma & immunology research |d 2009 |g 13(2021), 1 vom: 03. Jan., Seite 23-41 |w (DE-627)NLM195747658 |x 2092-7355 |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2021 |g number:1 |g day:03 |g month:01 |g pages:23-41 |
856 | 4 | 0 | |u http://dx.doi.org/10.4168/aair.2021.13.1.23 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 13 |j 2021 |e 1 |b 03 |c 01 |h 23-41 |